| P50 | author | Moacyr J B M Rego | Q83910368 |
| | Anderson Rodrigues de Almeida | Q88226772 |
| P2093 | author name string | Ivan R Pitta | |
| | Andréa Tavares Dantas | |
| | Angela Luzia Branco Pinto Duarte | |
| | Claudia Diniz Lopes Marques | |
| | Rafaela Silva Guimarães Gonçalves | |
| | Michelly C Pereira | |
| | Maira Galdino R Pitta | |
| P2860 | cites work | Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12 | Q24290619 |
| | A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R | Q24297906 |
| | Biology of IL-21 and the IL-21 receptor | Q24315354 |
| | Pathological versus protective functions of IL-22 in airway inflammation are regulated by IL-17A | Q24597173 |
| | IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner | Q24644925 |
| | Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling | Q24647357 |
| | Structure and signalling in the IL-17 receptor family | Q24648045 |
| | The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat | Q24648890 |
| | Interleukin 21 is a T helper (Th) cell 2 cytokine that specifically inhibits the differentiation of naive Th cells into interferon gamma-producing Th1 cells | Q24673146 |
| | T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines | Q24678115 |
| | Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells | Q27860460 |
| | The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells | Q27860620 |
| | Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17 | Q28213628 |
| | Transforming growth factor-beta induces development of the T(H)17 lineage | Q28237370 |
| | IL-21 enhances and sustains CD8+ T cell responses to achieve durable tumor immunity: comparative evaluation of IL-2, IL-15, and IL-21 | Q28270764 |
| | Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6 | Q28288702 |
| | T cells in systemic sclerosis: a reappraisal | Q38009282 |
| | Th17 cells in inflammation and autoimmunity | Q38242728 |
| | Efficacy of Secukinumab on Moderate-to-severe Plaque Psoriasis Affecting Different Body Regions: a Pooled Analysis of Four Phase 3 Studies. | Q38388241 |
| | Vasculopathy in scleroderma | Q38543688 |
| | New insights into the role of T cells in pathogenesis of psoriasis and psoriatic arthritis | Q38799600 |
| | Antibodies in the Treatment of Psoriasis: IL-12/23 p40 and IL-17a | Q38934594 |
| | Potential roles of interleukin-17A in the development of skin fibrosis in mice | Q39308063 |
| | Angiostatic activity of the antitumor cytokine interleukin-21. | Q39976585 |
| | Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis | Q40050137 |
| | Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial | Q40683161 |
| | Supernatants from culture of type I collagen-stimulated PBMC from patients with cutaneous systemic sclerosis versus localized scleroderma demonstrate suppression of MMP-1 by fibroblasts | Q42180802 |
| | IL-21 receptor signaling is integral to the development of Th2 effector responses in vivo | Q43459130 |
| | Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells | Q43991749 |
| | Alteration of Th17 and Treg cell subpopulations co-exist in patients affected with systemic sclerosis. | Q44939473 |
| | Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. | Q45939390 |
| | Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials. | Q45962385 |
| | Activated and resting regulatory T cell exhaustion concurs with high levels of interleukin-22 expression in systemic sclerosis lesions. | Q46050774 |
| | Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement | Q46474228 |
| | Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis | Q47671991 |
| | Corticosteroid inhibits chemokines production in systemic sclerosis patients | Q47817201 |
| | Vascular endothelial growth factor aggravates fibrosis and vasculopathy in experimental models of systemic sclerosis | Q47852702 |
| | Distinctive expression of interleukin-23 receptor subunits on human Th17 and γδ T cells. | Q50619892 |
| | Th-17 cytokines and interstitial lung involvement in systemic sclerosis. | Q51314108 |
| | Dysregulated interleukin-23 signalling contributes to the increased collagen production in scleroderma fibroblasts via balancing microRNA expression. | Q51390408 |
| | Elevated frequencies of CD4(+) IL-21(+) T, CD4(+) IL-21R(+) T and IL-21(+) Th17 cells, and increased levels of IL-21 in bleomycin-induced mice may be associated with dermal and pulmonary inflammation and fibrosis. | Q51672074 |
| | IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. | Q51745791 |
| | IL-22 capacitates dermal fibroblast responses to TNF in scleroderma. | Q52911127 |
| | The elevated expression of Th17-related cytokines and receptors is associated with skin lesion severity in early systemic sclerosis. | Q53663657 |
| | The interleukin 23 receptor gene does not confer risk to systemic sclerosis and is not associated with systemic sclerosis disease phenotype | Q57307094 |
| | Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis | Q58411438 |
| | TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells | Q28296956 |
| | IL-1 and IL-23 mediate early IL-17A production in pulmonary inflammation leading to late fibrosis | Q28476584 |
| | IL-23 drives a pathogenic T cell population that induces autoimmune inflammation | Q29547525 |
| | Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages | Q29547871 |
| | Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation | Q29614224 |
| | Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain | Q29614225 |
| | IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways | Q29614839 |
| | Development, cytokine profile and function of human interleukin 17-producing helper T cells | Q29617131 |
| | Matrix metalloproteinases and the regulation of tissue remodelling | Q29618747 |
| | Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla | Q30760660 |
| | The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFbeta and IFNgamma distinguishes SSc phenotypes | Q33470222 |
| | Bleomycin and IL-1beta-mediated pulmonary fibrosis is IL-17A dependent | Q33730117 |
| | Association of interleukin 23 receptor polymorphisms with anti-topoisomerase-I positivity and pulmonary hypertension in systemic sclerosis | Q33955502 |
| | Interleukin-26: an IL-10-related cytokine produced by Th17 cells | Q34384300 |
| | Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis | Q34400597 |
| | Interleukin-17A promotes functional activation of systemic sclerosis patient-derived dermal vascular smooth muscle cells by extracellular-regulated protein kinases signalling pathway | Q35047990 |
| | Mortality and causes of death in a Swedish series of systemic sclerosis patients | Q35547607 |
| | Tanshinone IIA attenuates interleukin-17A-induced systemic sclerosis patient-derived dermal vascular smooth muscle cell activation via inhibition of the extracellular signal-regulated kinase signaling pathway | Q35565348 |
| | Histopathological cutaneous alterations in systemic sclerosis: a clinicopathological study | Q35620376 |
| | Is systemic sclerosis an antigen-driven T cell disease? | Q35799608 |
| | Increased frequency of circulating Th22 in addition to Th17 and Th2 lymphocytes in systemic sclerosis: association with interstitial lung disease | Q35840797 |
| | Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database | Q35953368 |
| | Scleroderma: from cell and molecular mechanisms to disease models | Q36259889 |
| | Interleukin-22 inhibits bleomycin-induced pulmonary fibrosis | Q36656518 |
| | Autoimmunity in systemic sclerosis: current concepts | Q36821512 |
| | Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma | Q36871425 |
| | Th17 T cells: linking innate and adaptive immunity | Q37006577 |
| | Cell adhesion molecules regulate fibrotic process via Th1/Th2/Th17 cell balance in a bleomycin-induced scleroderma model. | Q37069130 |
| | The inflammatory Th 17 subset in immunity against self and non-self antigens | Q37103780 |
| | Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer | Q37284326 |
| | Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations | Q37453883 |
| | Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility | Q37460609 |
| | The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin | Q37662888 |
| | Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts | Q37691158 |
| | Increased frequency of Th17 cells in systemic sclerosis is related to disease activity and collagen overproduction | Q37691199 |
| | Recent advances in IL-22 biology. | Q37851777 |
| | Interleukin-23: a key cytokine in inflammatory diseases | Q37876404 |
| P433 | issue | 1 | |
| P304 | page(s) | 1-9 | |
| P577 | publication date | 2017-12-19 | |
| P1433 | published in | Autoimmunity | Q4826348 |
| P1476 | title | IL-17 and related cytokines involved in systemic sclerosis: Perspectives | |
| P478 | volume | 51 | |